Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Depreciation & Amortization (CF) (2022 - 2025)

Taysha Gene Therapies' Depreciation & Amortization (CF) history spans 4 years, with the latest figure at $200000.0 for Q3 2025.

  • For Q3 2025, Depreciation & Amortization (CF) fell 33.33% year-over-year to $200000.0; the TTM value through Sep 2025 reached $1.1 million, down 13.25%, while the annual FY2024 figure was $1.2 million, 9.19% down from the prior year.
  • Depreciation & Amortization (CF) for Q3 2025 was $200000.0 at Taysha Gene Therapies, down from $300000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $400000.0 in Q4 2022 and bottomed at $200000.0 in Q3 2025.
  • The 4-year median for Depreciation & Amortization (CF) is $300000.0 (2022), against an average of $316133.3.
  • The largest annual shift saw Depreciation & Amortization (CF) surged 33.33% in 2023 before it tumbled 33.33% in 2025.
  • A 4-year view of Depreciation & Amortization (CF) shows it stood at $400000.0 in 2022, then decreased by 8.5% to $366000.0 in 2023, then dropped by 12.57% to $320000.0 in 2024, then plummeted by 37.5% to $200000.0 in 2025.
  • Per Business Quant, the three most recent readings for TSHA's Depreciation & Amortization (CF) are $200000.0 (Q3 2025), $300000.0 (Q2 2025), and $300000.0 (Q1 2025).